-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
news
newsToday ASO manufacturer Ionis announced a phase II clinical result of acromegaly of its liver-targeted growth hormone receptor (GHR) trans-nucleic acid drug Cemdelirsen (IONIS-GHR-L)
Drug source analysis
Drug source analysisToday is World Acromegaly Day.
Cemdelirsen is a GalNac-coupled ASO, so it only has a significant effect on liver GHR
ASO is a treatment with a longer history than RNAi and mRNA, but because the delivery problem has not been solved, progress has been slow in the first two decades
The discovery of GalNac completely changed the fate of RNA drugs, but also restricted the target to the liver.